140 related articles for article (PubMed ID: 37208840)
1. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Hagio K; Kikuchi J; Takada K; Tanabe H; Sugiyama M; Ohhara Y; Amano T; Yuki S; Komatsu Y; Osawa T; Hatanaka KC; Hatanaka Y; Mitamura T; Yabe I; Matsuno Y; Manabe A; Sakurai A; Ishiguro A; Takahashi M; Yokouchi H; Naruse H; Mizukami Y; Dosaka-Akita H; Kinoshita I
Cancer Sci; 2023 Aug; 114(8):3385-3395. PubMed ID: 37208840
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Kikuchi J; Ohhara Y; Takada K; Tanabe H; Hatanaka K; Amano T; C Hatanaka K; Hatanaka Y; Mitamura T; Kato M; Shibata Y; Yabe I; Endoh A; Komatsu Y; Matsuno Y; Sugiyama M; Manabe A; Sakurai A; Takahashi M; Naruse H; Torimoto Y; Dosaka-Akita H; Kinoshita I
Jpn J Clin Oncol; 2021 Apr; 51(5):753-761. PubMed ID: 33532831
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Comprehensive Genomic Profiling Tests for Gastrointestinal Cancers: Experience from Tokushima University Hospital.
Sato Y; Okada Y; Fujino Y; Kawaguchi T; Kida Y; Mitsui Y; Tanaka H; Tomonari T; Kitamura S; Okamoto K; Kawano Y; Miyamoto H; Sogabe M; Takayama T
J Med Invest; 2023; 70(1.2):154-159. PubMed ID: 37164713
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract][Full Text] [Related]
6. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
7. An approach for improvement of the accuracy of cancer gene panel testing.
Imoto K; Yamamoto H; Ohkawa C; Shimada N; Ikuzawa R; Takeda H; Ohhara T; Kojima Y; Furuya N; Motoyoshi A; Migita O; Kuga A; Keira T; Wakamatsu H; Sato T; Oike N; Koike J; Yamano Y; Sunakawa Y
Int J Clin Oncol; 2024 May; 29(5):571-581. PubMed ID: 38472663
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers.
Ueda T; Tsubamoto H; Takimoto Y; Isono-Taniguchi R; Narita S; Nakagawa K; Wakimoto YU; Nishimura Y; Muroi Y; Nagahashi M; Hirota S; Sawai H; Shibahara H
Anticancer Res; 2023 May; 43(5):2091-2101. PubMed ID: 37097652
[TBL] [Abstract][Full Text] [Related]
11. Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital.
Uehara Y; Koyama T; Katsuya Y; Sato J; Sudo K; Kondo S; Yoshida T; Shoji H; Shimoi T; Yonemori K; Yamamoto N
JAMA Netw Open; 2023 Sep; 6(9):e2333188. PubMed ID: 37713200
[TBL] [Abstract][Full Text] [Related]
12. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
Kubo T; Sunami K; Koyama T; Kitami M; Fujiwara Y; Kondo S; Yonemori K; Noguchi E; Morizane C; Goto Y; Maejima A; Iwasa S; Hamaguchi T; Kawai A; Namikawa K; Arakawa A; Sugiyama M; Ohno M; Yoshida T; Hiraoka N; Yoshida A; Yoshida M; Nishino T; Furukawa E; Narushima D; Nagai M; Kato M; Ichikawa H; Fujiwara Y; Kohno T; Yamamoto N
ESMO Open; 2024 Apr; 9(4):102981. PubMed ID: 38613908
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study.
Matsuoka A; Fujimori M; Koyama T; Sato A; Mori K; Hirata M; Tanabe N; Nakachi K; Kato S; Okamoto H; Ogawa K; Komatsu H; Iwasaku M; Miyaji T; Uchitomi Y
BMJ Open; 2023 Nov; 13(11):e072472. PubMed ID: 37996226
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
Hilal T; Nakazawa M; Hodskins J; Villano JL; Mathew A; Goel G; Wagner L; Arnold SM; DeSimone P; Anthony LB; Hosein PJ
BMC Cancer; 2017 Aug; 17(1):602. PubMed ID: 28854908
[TBL] [Abstract][Full Text] [Related]
15. [Questionnaire Survey on the Timing of Comprehensive Genomic Profiling for Advanced Recurrent Colorectal Cancer and Its Impact on Patients].
Yarimizu A; Kuribayashi M; Nomura K; Kimura K; Takenaka Y; Song J; Ohashi E; Nishimura Y; Demachi T; Hirata M; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
Gan To Kagaku Ryoho; 2023 Aug; 50(8):891-893. PubMed ID: 37608415
[TBL] [Abstract][Full Text] [Related]
16. [Development of a System for Providing Cancer Genomic Medicine in Hokkaido-From the Standpoint of a Designated Core Hospital for Cancer Genomic Medicine].
Kinoshita I; Kikuchi J; Ohhara Y; Amano T; Akita H
Gan To Kagaku Ryoho; 2021 Jul; 48(7):882-886. PubMed ID: 34267021
[TBL] [Abstract][Full Text] [Related]
17. Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial.
Ishimaru S; Shimoi T; Sunami K; Nakajima M; Ando Y; Okita N; Nakamura K; Shibata T; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2024 Feb; 29(2):89-95. PubMed ID: 38112833
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
19. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
20. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
